Once the form has been completed and submitted, a member of our team will contact you.
Please note that all information provided is kept confidential in a secure database and will be used for study recruitment purposes only.
This form is protected by reCAPTCHA and Google's Privacy Policy and Terms of Service apply. By completing this form, you consent to share your information in accordance with our Terms of Use et privacy Policy.
ACT18018 is a phase II study of the molecule Itepekimab in the management of non-cystic fibrosis bronchiectasis.
You may receive different doses of the investigational molecule or a placebo. The treatment is administered by subcutaneous injection.
To participate, you must have a received a diagnosis of non-cystic fibrosis bronchiectasis.
Clic here to access the official record from the National Library of Medicine for this study
Monday : 8 h 30 à 12 h et 13 h à 17 h
Tuesday : 8 h 30 à 12 h et 13 h à 17 h
Wednesday : 8 h 30 à 12 h et 13 h à 17 h
Thursday : 8 h 30 à 12 h et 13 h à 17 h
Friday : 8 h 30 à 12 h
Saturday : Closed
Sunday : Closed
This form is protected by reCAPTCHA and Google's Privacy Policy and Terms of Service apply. By completing this form, you consent to share your information in accordance with our Terms of Use et privacy Policy.
© 2024, All rights reserved, CIC Mauricie inc.
